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Ewing sarcoma (ES) is an aggressive bone and soft tissue tumor of putative stem cell ori-
gin that predominantly occurs in children and young adults. Although most patients with
localized ES can be cured with intensive therapy, the clinical course is variable and up to
one third of patients relapse following initial remission. Unfortunately, little is yet known
about the biologic features that distinguish low-risk from high-risk disease or the mech-
anisms of ES disease progression. Recent reports have suggested that putative cancer
stem cells exist in ES and may contribute to an aggressive phenotype. The cell surface
receptor leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) is a somatic
stem cell marker that functions as an oncogene in several human cancers, most notably
colorectal carcinoma. LGR5 is a receptor for the R-spondin (RSPO) family of ligands and
RSPO-mediated activation of LGR5 potentiates Wnt/β-catenin signaling, contributing to
stem cell proliferation and self-renewal. Given its presumed stem cell origin, we investi-
gated whether LGR5 contributes to ES pathogenesis. We found that LGR5 is expressed
by ES and that its expression is relatively increased in cells and tumors that display a more
aggressive phenotype. In particular, LGR5 expression was increased in putative cancer
stem cells. We also found that neural crest-derived stem cells express LGR5, raising the
possibility that expression of LGR5 may be a feature of ES cells of origin. LGR5-high ES
cells showed nuclear localization of β-catenin and robust activation of TCF reporter activity
when exposed to Wnt ligand and this was potentiated by RSPO. However, modulation of
LGR5 or exposure to RSPO had no impact on proliferation confirming that Wnt/β-catenin
signaling in ES cells does not recapitulate signaling in epithelial cells. Together these stud-
ies show that the RSPO-LGR5-Wnt-β-catenin axis is present and active in ES and may
contribute to tumor pathogenesis.
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INTRODUCTION
Ewing sarcoma (ES) is a malignant tumor of the bone and soft
tissue that can present at any age but predominantly occurs
in adolescents and young adults. These tumors are genetically
defined by recurrent chromosomal translocations that result in
the creation of novel fusion oncogenes, most commonly EWS-
FLI1 (Balamuth and Womer, 2010). Clinically, these tumors often
have an aggressive course with one quarter of patients present-
ing with gross metastatic disease at the time of diagnosis. In
addition, nearly one third of patients will relapse after an initial
clinical remission and patients who have metastatic or relapsed
ES have 5-year event free survival rates of only 10–20% (Bala-
muth and Womer, 2010). Unfortunately, there are no clinical or
pathologic criteria apart from metastases that can reliably pre-
dict whether a newly diagnosed patient with ES is likely to be
cured or to relapse. Histologically, tumors are characterized by an
undifferentiated small round blue cell phenotype with features
of primitive neuroectodermal cells. Although predominantly a
bone and connective tissue tumor, clinically ES can present in
multiple organs and tissue types throughout the body, suggest-
ing a relatively undifferentiated and potentially highly migratory
cell of origin (Meltzer, 2007). Indeed, current evidence supports
the hypothesis that ES arise from either mesenchymal stem cells
(MSC) or neural crest stem cells (NCSC) or their early progeni-
tors (Staege et al., 2004; Tirode et al., 2007; Riggi et al., 2008; von
Levetzow et al., 2011). Importantly, poorly differentiated tumors
in other classes of human malignancy often express stem cell-
associated markers and an undifferentiated phenotype combined
with high-level expression of stem cell genes is associated with
worse clinical outcomes (Phillips et al., 2006; Ben-Porath et al.,
2008; Spike et al., 2012). The stem cell phenotype and aggressive
nature of ES raise the question of whether stem cell markers could
be useful in understanding the origin and pathogenesis of this
enigmatic disease.
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Leucine-rich repeat-containing G-protein coupled receptor 5
(LGR5) is a seven transmembrane spanning receptor that has
recently been identified as a somatic stem cell marker that plays key
functional roles in both normal development and cancer. Mouse
studies have demonstrated that Lgr5 is widely expressed during
embryonic development but expression in postnatal tissues is lim-
ited to discrete stem cell populations (Barker et al., 2007). Such
stem cells can be found in the small and large intestine, stom-
ach, hair follicles, and kidney (Barker et al., 2007, 2010, 2012; Jaks
et al., 2008). The self-renewal and proliferation of normal murine
intestinal stem cells (ISC) is dependent on Lgr5 (Barker et al.,
2007). Significantly, Lgr5+ ISC have also recently been identified
as both the cells of origin for murine intestinal tumors and tumor-
maintaining cancer stem cells in established adenomas (Barker
et al., 2009; Schepers et al., 2012). Studies of human cancer cell
lines have now confirmed that LGR5 promotes the growth and/or
survival of colorectal and basal cell carcinoma (McClanahan et al.,
2006; Tanese et al., 2008), glioblastoma (Nakata et al., 2013), and
neuroblastoma (Balamuth et al., 2010). Thus, LGR5 has now been
shown to contribute functionally to normal and malignant biol-
ogy in tissues of both epithelial and neural origin. To determine if
high levels of LGR5 are associated with a more aggressive clinical
course, retrospective studies of archived tumors were undertaken
and showed diminished survival in gastrointestinal carcinoma and
glioblastoma patients whose tumors expressed high levels of LGR5
(Becker et al., 2010; Wu et al., 2012; Nakata et al., 2013). In addi-
tion, in the case of colorectal carcinoma, LGR5 is expressed by a
subpopulation of cells with stem cell-like properties (i.e., cancer
stem cells or CSC) (Kemper et al., 2012; Kobayashi et al., 2012).
The LGR5+ colorectal CSC have increased clonogenic and tumori-
genic potential compared to bulk tumor cells and lose expression
of LGR5 upon in vitro differentiation (Kemper et al., 2012). Gene
expression profiling experiments have also demonstrated that an
Lgr5-stem cell gene signature predicts disease relapse in colorectal
cancer patients (Merlos-Suarez et al., 2011). Thus, there is com-
pelling evidence in both human and murine intestinal tumors that
LGR5+ stem cells contribute to cancer initiation and progression
and that high LGR5 expression is associated with worse clinical
outcomes.
The mechanism by which LGR5 promotes stem cell self-renewal
and proliferation has only recently been elucidated. It is now
known that, along with its closely related homologs LGR4 and
LGR6, LGR5 functions to potentiate canonical Wnt/β-catenin sig-
naling (Carmon et al., 2011; de Lau et al., 2011; Glinka et al., 2011;
Gong et al., 2012). This potentiation of Wnt signaling is achieved
when LGR5 is bound by its ligand R-spondin (RSPO). RSPOs
are a recently described family of secreted proteins that function
as Wnt agonists and play pivotal roles as regulators of normal
embryonic development and stem cell proliferation (Glinka et al.,
2011). When RSPO binds to LGR5 the receptor associates with the
Frizzled/LRP complex to increase the activation of β-catenin and
downstream TCF reporter activity as well as non-canonical Wnt
signaling (Glinka et al., 2011). The potentiation of Wnt/β-catenin
signaling is now believed to mediate the self-renewal and prolif-
eration of LGR5+ stem cells, both normal and malignant, and
provides a mechanistic link between LGR5, Wnt signaling, cancer
stem cells, and cancer progression (Clevers and Nusse, 2012).
Given the presumed stem cell origin of ES, the presence of
RSPO2 in developing bone (Friedman et al., 2009) and prior evi-
dence that Wnt signaling is abnormal in these tumors (Uren et al.,
2004; Navarro et al., 2010; Vijayakumar et al., 2011) we hypoth-
esized that LGR5 and its downstream impact on Wnt signaling
might contribute to ES pathogenesis. In the current study we have
investigated this hypothesis using studies of ES primary tumors
and cell lines and normal neuro-MSC, candidate cells of ES origin.
Our findings indicate that LGR5 is indeed expressed by some pop-
ulations of ES cells and that these cells upregulate Wnt/β-catenin
signaling when exposed to RSPO. Together our studies suggest that
LGR5-mediated potentiation of Wnt signaling may be an impor-
tant contributor to ES initiation and maintenance, especially in
RSPO-rich microenvironments like developing bone.
MATERIALS AND METHODS
TUMOR SAMPLES AND CELL LINES
Primary tumor RNA was obtained from Children’s Hospital Los
Angeles (CHLA) and Children’s Oncology Group (COG) tumor
biorepositories. All primary tissue samples were coded according
to an anonymous numbering scheme and acquired in accor-
dance with approval from the CHLA Committee for Clinical
Investigation. Primary tumor expression data were kindly pro-
vided by the COG (Lawlor, unpublished data). ES cell lines were
kindly provided by Dr. Timothy Triche (CHLA, Los Angeles, CA,
USA), Dr. Heinrich Kovar (CCRI, St. Anna Kinderkrebsforschung,
Vienna, Austria), and the COG cell bank (cogcell.org) and identi-
ties confirmed by short tandem repeat profiling courtesy of Dr. Pat
Reynolds (Texas Tech University, Lubbock, TX, USA). All ES cell
lines were maintained in RPMI with l-glutamine and 10% FBS on
tissue culture treated polystyrene plates, except for CHLA25 and
STA-ET-8.2 cells. These cell lines were grown on plates coated with
fibronectin. Human bone marrow mesenchymal stem cell lines
(MSC; obtained from Dr. Darwin Prockop, Tulane University, New
Orleans, LA, USA), H1 and H9 human embryonic stem cell (ESC)
lines (Wicell, Madison, WI, USA) and ESC-derived neural crest
cells were cultured and differentiated using standard protocols as
previously described by our lab (Jiang et al., 2009; von Levetzow
et al., 2011). MRC5 fibroblasts were obtained from American Type
Culture Collection and maintained in DMEM with l-glutamine
and 10% FBS.
QUANTITATIVE REAL-TIME REVERSE TRANSCRIPTION PCR
cDNA was generated from RNA (iScript; Bio-Rad, Hercules,
CA, USA) and qRT-PCR was performed with validated TaqMan
primers (LGR5, CITED2, CYCLIND1, MYC, GAPDH, and 18S;
Life Technologies, Grand Island, NY, USA) or primers designed
using qPrimerDepot (primerdepot.nci.nih.gov) (Table 1) (Cui
et al., 2007). Assays were performed in triplicate using the Applied
Biosystems 7900HT Fast real-time PCR system or Roche Light
Cycler 480 and average Ct values were normalized relative to
GAPDH or 18S expression in the same sample.
IMMUNOCYTOCHEMISTRY
Cells were grown on fibronectin-coated chamber slides (Thermo
Fisher Scientific, Waltham, MA, USA), fixed in 4% paraformalde-
hyde, and permeabilized with 0.1% Triton X-100. After rinsing
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Table 1 | Prime sequences for RT-PCR.
Gene Forward primer sequence Reverse primer sequence
AXIN2 AAGTGCAAACTTTCGCCAAC ACAGGATCGCTCCTCTTGAA
CD44 GACAAGTTTTGGTGGCACG CACGTGGAATACACCTGCAA
CDC25A CCAGCCCCAAAGAGTCAAC AAGGTCCCTTGGGTCATTGT
EPHB2 CTCTACTGTAACGGGGACGG CCTTGAAAGTCCCAGATGGA
HIG2 CTTCTGCGCTGGTGCTTAGT GCAGAGAAACAGAGCTGCCT
ID2 GACAGCAAAGCACTGTGTGG TCAGCACTTAAAAGATTCCGTG
LEF1 TGGATCTCTTTCTCCACCCA CACTGTAAGTGATGAGGGGG
TROY CCCTCCTCCTCCTTACGAAC CCAGAGCGCTGCAGATAAC
GAPDH AAGGTGAAGGTCGGAGTCAA AATGAAGGGGTCATTGATGG
18S GCAATTATTCCCCATGAACGA GGCCTCACTAAACCATCCAAT
in phosphate-buffered saline (PBS) the slides were incubated for
1 h in blocking solution (1% BSA and 5% donkey serum in
PBS). Blocked slides were incubated with primary β-catenin anti-
body (1:300; BD Biosciences, San Jose, CA, USA) overnight at
4˚C, washed in PBS, incubated with Alexa Fluor 488-conjugated,
donkey-anti mouse secondary antibody (1:500; Life Technologies)
for 1 h, and then visualized with a Leica DMI6000 B Fluorescence
Microscope. Nuclei were counterstained with 4′,6-diamidino-2-
phenylindole (DAPI). Cytoplasmic and nuclear β-catenin staining
cells were manually counted in a minimum of three high-power
fields.
CELL SORTING FOR SUBPOPULATION STUDIES
For CD133 sorts, cultured STA-ET-8.2 cells were trypsinized and
resuspended in FcR Blocking Reagent (Miltenyi Biotec, Auburn,
CA, USA) with 0.5% bovine serum albumin (Sigma, St Louis, MO,
USA) in PBS. Mouse anti-human CD133/2-PE (Miltenyi) mono-
clonal antibody was then added (1:11 dilution) and incubated for
15 min at 4˚C in the dark. After two washes, cells were sorted on a
MoFlo Astrios instrument (Beckman Coulter) at the University of
Michigan Flow Cytometry Core. Positive and negative gates were
determined using IgG stained and unstained controls. TC71 and
MHH-ES cells were sorted on the basis of aldehyde dehydrogenase
activity using the Aldefluor® assay (Stem Cell Technologies, Van-
couver, BC, USA). Cells were analyzed and sorted as previously
described (Awad et al., 2010).
GENERATION OF STABLE KNOCKDOWN AND OVER-EXPRESSION CELL
LINES
For knockdown studies, cell lines were transduced with
pLKO.1-puro lentiviral short hairpin RNAs vectors targeting
LGR5 expression (shLGR5#1-TAAGTGCCAGAACTGCTATGG
and shLGR5#3-TTGTCCAAATTGCAGTAGAGC; Thermo Fisher
Scientific). Control cells were transduced with a non-silencing
small hairpin RNA vector containing an inert sequence
(shNS-CAACAAGATGAAGAGCACCAA). Cells were selected in
puromycin (1–2µg/mL) for at least 48 h before use in subsequent
experiments. For over-expression studies, cells were transduced
with a lentiviral pCL6 expression vector into which the full length
open reading frame for LGR5 cDNA (NP_003658; Thermo Scien-
tific, Clone ID BC09624) was cloned. The pCL6 vector is a mod-
ified version of the pCL1 vector including an internal ribosome
entry site and woodchuck hepatitis virus post-transcription
regulatory element up- and downstream, respectively, of the
EGFP reporter gene (Feldhahn et al., 2007; von Levetzow et al.,
2011). Control cells were transduced with empty vector that
lacked the LGR5 sequence (Empty). Cells were selected by
FACS on the basis of GFP expression. Lentiviral supernatant for
each construct was generated from plasmid-transfected 293FT
packaging cells as previously described (von Levetzow et al.,
2011).
TCF REPORTER ASSAY
To assess the transcriptional activity of the Wnt/β-catenin axis we
used previously characterized TCF-promoter luciferase-reporter
constructs (Fuerer and Nusse, 2010). The 7xTcf-FFluc//SV40-
mCherry (p7TFC) and 7xTcf-FFluc//SV40-PuroR (p7TFP) plas-
mids were purchased from Addgene (plasmids 24,307 and 24,308,
respectively). Cells were sorted for mCherry expression (p7TFC)
by FACS or cultured with puromycin (p7TFP) to select for cells
that were successfully transduced. To assess the effects of exoge-
nous Wnt ligand on ES cells we collected conditioned media
(CM) from control mouse fibroblasts (L-cells) or L-cells that have
been engineered to over-express Wnt3a (L-Wnt3a-cells) obtained
from the American Type Culture Collection (ATCC CRL-2648
and CRL-2647, respectively). The final dilution of L-cell CM
or Wnt3a CM was 1:2 in RPMI containing 5% FBS. Recom-
binant human RSPO2 (R&D Systems, Minneapolis, MN, USA)
was added to L-cell CM or Wnt3a CM at a concentration of
20 ng/mL. p7TFC and p7TFP-transduced cells were plated at a
density of 4.0× 104 cells/well on 96-well plates and allowed to
attach overnight. The cells were cultured for another 24 h in
standard RPMI with 10% FBS or treated with L-cell CM or
Wnt3a CM. Luciferase measurements were carried out using the
Luciferase Assay System (Promega) according to the manufac-
turer’s protocol and read on a Molecular Devices LMAX plate
reader. Measurements were normalized to mCherry mean flu-
orescent intensity for cells transduced with the p7TFC vector,
otherwise TCF reporter activity was expressed relative to the L-cell
CM control.
CELL PROLIFERATION ASSAYS
Cell growth was assessed using the CellTiter 96 AQueous One Solu-
tion Cell Proliferation Assay (Promega, Madison, WI, USA). Cells
were plated at a density of 5× 103 cells/well in 8-well replicates
on 96-well flat-bottomed plates, allowed to attach overnight, and
growth was assessed on Days 0, 2, and 4 post-attachment. For cells
grown in the presence of exogenous Wnt ligands, WNT3A (R&D
Systems), and/or RSPO2 (R&D Systems) were supplemented on
Days 0 and 3 at 500 and 20 ng/mL, respectively. The normalized
cell index was calculated relative to the Day 0 absorbance reading
minus background.
STATISTICAL ANALYSIS
Unless otherwise indicated data from all experiments are expressed
as mean± SEM from a minimum of three independent exper-
iments. The data was analyzed using GraphPad Prism software
by a Student’s t -test and a p value of <0.05 was considered
significant.
www.frontiersin.org April 2013 | Volume 3 | Article 81 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scannell et al. LGR5 in Ewing sarcoma
RESULTS
LGR5 IS EXPRESSED BY EWING SARCOMA AND NEURAL
CREST-DERIVED STEM CELLS
Ewing sarcoma are usually highly undifferentiated tumors that dis-
play features of both NCSC and MSC stem cells. Thus, although
their precise cellular ontogeny remains to be fully elucidated, ES
are presumed to arise from malignant transformation of nor-
mal NCSC and/or MSC. We therefore sought to determine if
LGR5 is expressed by ES and the stem cells from which they are
thought to arise. To address this we analyzed the expression of
LGR5 in a cohort of 49 primary ES tumor samples and 15 ES
cell lines. Unfortunately, the specificity of commercially available
antibodies for studies of human LGR5 remains inadequate for
immuno-histochemical studies so we limited our evaluation of
LGR5 expression to quantitative RT-PCR analysis. As shown,LGR5
was widely detectable in both ES tumors and cell lines, however,
the level of expression was highly variable (Figures 1A,B).
Given its designation as a stem cell marker in epithelial tis-
sues we next assessed whether LGR5 might be expressed by
NCSC and/or MSC. To address this we evaluated adult human
bone marrow-derived MSC as well as human ESC-derived NCSC
and their MSC progeny, neural crest-derived MSC (NC-MSC) as
previously described by our group (von Levetzow et al., 2011).
Significantly, our analyses revealed that undifferentiated NCSC
express relatively high levels of LGR5 whereas the transcript is
undetectable in adult bone marrow-derived MSC (Figure 2A).
Consistent with this observation, LGR5 expression declined when
NCSC were differentiated toward an MSC identity (NC-MSC)
(Figure 2A). Interestingly, the level of LGR5 expression in these
neural crest-derived stem cells was comparable to that of ES cell
lines (Figure 2A). To determine if the observed differential expres-
sion of LGR5 by neural crest cells was merely an artifact of the
human ESC culture system we next interrogated publicly avail-
able gene expression data that compared murine bone marrow
stem cells of mesodermal origin to bone marrow stem cells of
neural crest origin (GEO accession 30,419) (Wislet-Gendebien
et al., 2012). Interestingly, consistent with our human cell stud-
ies, murine bone marrow-derived stem cells of neural crest origin
expressed higher levels of Lgr5 than MSC of mesodermal origin
(Figure 2B).
Together these studies show that LGR5 is expressed, to varying
degrees, by established ES tumors and cell lines. Moreover, they
FIGURE 1 | Leucine-rich repeat-containing G-protein coupled receptor 5
is expressed by Ewing sarcomas. qRT-PCR analysis revealed low to very
high-level expression of LGR5 in (A) 49 primary Ewing sarcoma (ES) and (B)
15 ES cell lines. For primary tumors levels of expression relative to GAPDH
were <0.001% in 1 tumor, 0.001–0.01% in 7 tumors, 0.01–0.1% in 17 tumors,
0.1–1% in 12 tumors, 1–10% in 9 tumors, and 10–100% in 3 tumors.
FIGURE 2 | Leucine-rich repeat-containing G-protein coupled receptor 5
is expressed by neural crest stem cells (NCSC). (A) qRT-PCR analysis of
human embryonic stem cells (hESC), hESC-derived NCSC (hNCSC),
hNCSC-derived mesenchymal stem cells (hNC-MSC), bone marrow-derived
mesenchymal stem cells (hBM-MSC), and human lung embryo fibroblasts
(MRC5) showed that undifferentiated hNCSC express the highest levels of
LGR5. (B) Murine bone marrow stromal cells of neural crest origin express
higher levels of Lgr5 than cells of mesodermal origin (from publically available
microarray data GEO accession GSE30419) (Wislet-Gendebien et al., 2012).
N =3±SEM. Lines represent arithmetic means of replicate samples.
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demonstrate that while LGR5 is not highly expressed by MSC of
mesodermal origin, it is expressed by neural crest-derived stem
cells, in particular undifferentiated NCSC.
LGR5 EXPRESSION IS ELEVATED IN CLINICALLY AGGRESSIVE ES AND
IN PUTATIVE ES CANCER STEM CELLS
Over-expression of LGR5 has been linked to clinically aggressive
disease in colorectal carcinoma as well as several other epithelial
malignancies. Therefore, we sought to determine if high expres-
sion of LGR5 might also be associated with aggressive disease in ES.
To address this we first compared LGR5 expression in the CHLA9
and CHLA10 cell lines, which were derived from the same patient
prior to (CHLA9) and after (CHLA10) chemotherapy. It is note-
worthy that the CHLA10 cell line was derived from a metastatic
focus and therefore represents a progressive state of disease. As
shown, LGR5 levels were found to be 10-fold higher in CHLA10
than CHLA9 cells (Figure 3A). To evaluate whether clinically
aggressive ES express higher levels of LGR5 in vivo we interro-
gated whole genome expression data that were generated from
primary human tumor samples (ERL unpublished data, kindly
provided by the COG). LGR5 expression levels from diagnostic
biopsies were compared in 4 patients who succumbed to rapidly
progressive disease (survival 5–13 months) and 10 patients who
remained disease free for at least 48 months. LGR5 expression was
found to be extremely high in three of four patients with aggressive
disease and mean expression was significantly higher than in long
term event free survivors (Figure 3B). Interestingly, two of the
three patients with the highest expression of LGR5 had primary
drug-resistant tumors.
It has been previously reported that LGR5 expression is
enriched in cancer cells with stem cell-like properties (Merlos-
Suarez et al., 2011; Kemper et al., 2012; Kobayashi et al., 2012;
Nakata et al., 2013). These cells have the unique ability to self-
renew and differentiate compared to bulk tumor cells and can
contribute to metastasis and drug resistance (Visvader and Lin-
deman, 2012). Although putative CSC were identified in a small
cohort of primary tumors (Suva et al., 2009) it has been chal-
lenging to isolate putative CSC from established ES cell lines.
Nevertheless, CD133 surface expression (Jiang et al., 2010) and
high-level of ALDH activity (Awad et al., 2010) have been used
to successfully enrich for CSC populations in STA-ET-8.2 and
MHH-ES and TC71 cells, respectively. Therefore, we used these
previously reported ES cell lines and CSC-enrichment assays to
determine whether LGR5 expression is up regulated in putative
CSC. qRT-PCR analysis of CD133-sorted STA-ET-8.2 popula-
tions consistently demonstrated increased expression of LGR5 in
the CSC-enriched CD133+ fraction (Figure 3C). Similarly, levels
of LGR5 were reproducibly higher in MHH-ES cells that dis-
played high ALDH activity than MHH-ES cells with low ALDH
activity (Figure 3D). In contrast, data from TC71 were incon-
sistent. Although increased expression of LGR5 was detected in
ALDHhigh CSC populations in one experiment this finding was not
reproducible in two other independent experiments (Figure 3D).
In summary, these findings suggest that LGR5 is highly
expressed by at least some populations of CSC-like ES cells. In
addition, they provide preliminary evidence in support of the
hypothesis that over-expression of LGR5 in primary tumors may
be associated with an aggressive drug-resistant clinical phenotype.
FIGURE 3 | Leucine-rich repeat-containing G-protein coupled
receptor 5 is increased in aggressive disease and putative cancer
stem cells. (A) Metastatic tumor-derived CHLA10 cells express higher
levels of LGR5 than CHLA9 cells, which were derived from the primary
tumor at diagnosis. (B) LGR5 expression was found by microarray
analysis to be increased in tumors from 4 patients with rapidly
progressive and fatal primary ES (DOD-dead of disease) compared to 10
patients with at least 48 months disease free survival (LTS-long term
survivors). (C) LGR5 levels are higher in CD133+ compared to CD133−
STA-ET-8.2 cells. Data from two independent sorting experiments are
shown and expression on the y -axis is of CD133+ cells relative to the
corresponding CD133− cells. (D) LGR5 expression is increased in
ALDHhigh compared to ALDHlow MHH-ES and TC71 cells. Data from three
independent sorts are shown and expression on the y -axis is that of
ALDHhigh relative to the corresponding ALDHlow cells. The horizontal line in
(B–D) all represent arithmetic mean values.
www.frontiersin.org April 2013 | Volume 3 | Article 81 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scannell et al. LGR5 in Ewing sarcoma
Studies are ongoing to determine if this association can be
validated in a larger cohort of tumors.
R-SPONDIN POTENTIATES Wnt/β-CATENIN SIGNALING IN AN
LGR5-DEPENDENT MANNER
Given its role as a potentiator of Wnt/β-catenin signaling, we
hypothesized that ES cells with high levels of LGR5 expression
would demonstrate relatively high Wnt/β-catenin transcriptional
activity. To address this we first evaluated basal levels of the
Wnt/β-catenin axis in ES cells that were grown in standard tis-
sue culture conditions. To begin we measured the expression of
known Wnt/β-catenin target genes in three different ES cell lines
(A673, CHLA25, and TC71) and discovered that although the lev-
els of gene expression varied significantly among the three cell
lines, there was no correlation with LGR5 levels (Figure 4A). In
support of this, we observed no significant or reproducible change
in the expression of Wnt/β-catenin target genes following LGR5
knockdown (Figure 4B). In particular, loss of LGR5 did not result
in down-regulation of Wnt targets suggesting that, in the context of
standard tissue culture (i.e., in the absence of exogenous RSPO),
LGR5 has little impact on Wnt/β-catenin transcriptional activ-
ity (Figure 4B). Next, we used TCF-promoter luciferase-reporter
assays to directly measure the level of TCF transcriptional activ-
ity in CHLA25 ES cells before and after LGR5 knockdown. These
assays confirmed that LGR5 knockdown had only minimal impact
on basal Wnt/β-catenin transcriptional activity in standard culture
conditions (Figure 4C). Thus, in standard culture conditions ES
cells show only minimal canonical Wnt activity and this activity is
not impacted by LGR5.
Next, we investigated whether the Wnt/β-catenin axis is intact
in ES cells and capable of activation in the presence of exoge-
nous ligands. In particular, we hypothesized that cells with high
levels of endogenous LGR5 expression might be susceptible
to RSPO-mediated potentiation of Wnt/β-catenin signaling. To
address this we first evaluated sub-cellular localization of β-
catenin in ES cells before and after exposure to exogenous Wnt3a.
Consistent with a previous report (Uren et al., 2004), ES cells
demonstrated little evidence of β-catenin in their nuclei under
basal conditions (Figure 5A). In contrast, exposure of ES cells to
Wnt3a CM resulted in robust nuclear translocation of β-catenin
(Figures 5A,B). Indeed, Wnt3a induced nuclear translocation of
β-catenin in all three lines irrespective of their endogenous LGR5
expression levels (Figure 5B). Although there are four RSPOs,
RSPO2 has been shown to have the highest affinity for both LGR4
and LGR5 (Carmon et al., 2011). In addition, RSPO2 is highly
expressed in developing bone (Nam et al., 2007; Hankenson et al.,
2010). Therefore, we next exposed ES cells to RSPO2 either alone
or in combination with Wnt3a and measured β-catenin nuclear
localization. The presence of RSPO2 alone had no effect on sub-
cellular localization of β-catenin (Figures 5A,B). In contrast, the
combination of Wnt3a CM plus RSPO2 resulted in potentia-
tion of Wnt/β-catenin signaling in CHLA25 cells as demonstrated
by further up-regulation and nuclear translocation of β-catenin
(Figures 5A,B). We also measured the expression of the Wnt/β-
catenin target gene AXIN2 in these four conditions. In keeping
with increased nuclear localization of β-catenin, we observed
induction of AXIN2 expression following Wnt3a stimulation and,
in CHLA25 cells, potentiation of this up-regulation in the presence
of RSPO2 (Figure 6A). Likewise, TCF reporter activity increased
in a stepwise fashion when cells were exposed first to Wnt3a alone
and then both Wnt3a and RSPO2 together (Figure 6B). Notably,
potentiation of Wnt/β-catenin signaling by RSPO2 was only sta-
tistically significant in CHLA25 cells, the cell line with the highest
level of LGR5. To determine if LGR5 was responsible for mediat-
ing this robust RSPO2-dependent potentiation of Wnt/β-catenin
signaling we evaluated the consequences of LGR5 knockdown on
FIGURE 4 | No correlation exists between LGR5 expression and
Wnt/β-catenin activity in ES cells in standard culture. (A) Canonical
Wnt/β-catenin target gene expression was measured by qRT-PCR in ES cell
lines. There was no apparent correlation between LGR5 expression and
Wnt/β-catenin target genes AXIN2 and CD44. (B) No consistent or significant
change occurs in the expression of a panel of Wnt/β-catenin target genes
following LGR5 knockdown. The dotted line represents a ratio of 1 between
shLGR5#1 and shNS cells. (C) LGR5 knockdown does not measurably
decrease Wnt/β-catenin transcriptional activity. Luciferase activity was
determined using TCF reporter-transduced cell lines as described in Section
“Material and Methods.” All data shown is from three independent
experiments and error bars are SEM.
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FIGURE 5 | ExogenousWnt3a induces nuclear localization of β-catenin
and is potentiated by RSPO2. (A) CHLA25 cells grown in the presence of
Wnt3a conditioned medium (CM) induced nuclear localization of β-catenin and
this was robustly potentiated by the addition of RSPO2. RSPO2 alone had no
effect on β-catenin nuclear localization. (B)The percentage of CHLA25, A673,
and TC71 cells with nuclear β-catenin all increased with Wnt3a CM, but
CHLA25 showed the greatest increase in nuclear localization with the addition
of RSPO2. Data from three independent experiments and error bars are SEM.
FIGURE 6 | RSPO2 potentiatesWnt/β-catenin signaling in LGR5-high ES
cells. (A) Exposure of ES cell lines to Wnt3a conditioned medium (CM)
increased AXIN2 expression, but expression was only potentiated by RSPO2
in the LGR5 -high cell line, CHLA25. (B)TCF reporter activity was induced in
ES cells exposed to Wnt3a CM, but was only potentiated in CHLA25 cells by
the addition of RSPO2. (C)TCF reporter activity was measured in control and
LGR5 knockdown CHLA25 cells following exposure to Wnt3a with/without
RSPO2. Reporter activity in the presence of RSPO2 was significantly
diminished in LGR5 knockdown cells. All data shown is from three
independent experiments and error bars are SEM.
this signaling axis in CHLA25 cells. Significantly, in the context
of Wnt3a and RSPO2 ligands, knockdown of LGR5 resulted in
reduced potentiation of Wnt/β-catenin transcriptional activity
(Figure 6C). Interestingly, we also observed down-regulation of
TCF reporter activity in Wnt3a-only treated cells (Figure 6C) sug-
gesting that low level endogenous production of RSPO by CHLA25
cells might also contribute to potentiation of the Wnt/β-catenin
axis in a Wnt-rich microenvironment.
LGR5 DOES NOT PROMOTE ES CELL PROLIFERATION IN VITRO
Leucine-rich repeat-containing G-protein coupled receptor 5
functions as a growth-promoting oncogene in several adult malig-
nancies including gastrointestinal tumors and gliomas (McClana-
han et al., 2006; Tanese et al., 2008; Nakata et al., 2013). In
addition, LGR5 was recently shown to promote proliferation of
neuroblastoma (Balamuth et al., 2010), another highly aggressive
pediatric tumor of neural crest origin (Jiang et al., 2011). In order
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to determine if LGR5 promotes ES cell proliferation we gener-
ated ES cell lines with altered levels of expression of LGR5 as
a consequence of stable RNA-interference-mediated knockdown
or ectopic over-expression (Figures 7A,B). As shown, although
reduced proliferation of the CHLA25 cell line was observed with
one LGR5-targeted knockdown sequence (shLGR5#1), this phe-
notype was not observed in A673 cells (Figure 7C). In addition,
a second LGR5-targeted shRNA sequence (shLGR5#3) did not
inhibit proliferation in any of the cell lines (Figure 7C). Forced
over-expression of LGR5 in the LGR5- low cell line A673 also had
no impact on proliferation (Figure 7D). Cellular viability was also
measured by trypan blue staining and no change was observed in
any of the cell lines followingLGR5 knockdown or over-expression
(data not shown). Therefore, in contrast to neuroblastoma cells
(Balamuth et al., 2010), LGR5 does not promote the proliferation
of ES cells in standard in vitro culture conditions.
Next, we repeated proliferation studies in non-transduced, par-
ent cells in the presence of WNT and RSPO, reasoning that changes
in proliferation downstream of Wnt/β-catenin activation would
only be apparent in cells that were exposed to the necessary ligands.
Interestingly, no change in proliferation was observed in either
A673 or CHLA25 cells with the addition of WNT3A and/or RSPO2
(Figure 7E). Studies are ongoing to evaluate the phenotypic con-
sequences of LGR5-mediated potentiation of Wnt/β-catenin sig-
naling but these data support prior observations that this pathway
does not promote ES cell proliferation (Endo et al., 2008).
In summary, these studies demonstrate that the WNT/β-
catenin signaling axis is present and intact in ES cells but is not
activated in standard cell culture conditions. Addition of Wnt lig-
and to ES cell culture media can activate the canonical pathway
and, in CHLA25 cells that express high levels of LGR5, activation
is potentiated by the addition of RSPO2. The generalizability of
this observation to other LGR5 over-expressing ES cells and pri-
mary tumors now requires further investigation to fully elucidate
the contribution of the LGR5-WNT/β-catenin signaling axis to ES
pathogenesis.
DISCUSSION
In this study we have, for the first time, shown that LGR5 is
expressed by ES cells, both in the context of primary tumors and
in cell culture, but that expression levels vary significantly among
different ES cell populations. In particular, we found that levels
of LGR5 were highest in putative ES cancer stem cells as well as
primary tumor biopsies obtained from patients with rapidly pro-
gressive and drug-resistant disease. The wide range and pattern
of LGR5 expression in ES tumor samples and cell lines is consis-
tent with patterns of LGR5 expression that have been discovered
in other human cancers. Specifically, recent studies of colorectal
carcinoma support the hypothesis that LGR5 is a marker of can-
cer stem cells in these tumors (Kemper et al., 2012; Kobayashi
et al., 2012). In addition, studies of colorectal and gastric car-
cinoma, glioblastoma, and esophageal adenocarcinoma have all
FIGURE 7 | Leucine-rich repeat-containing G-protein coupled receptor 5
does not promote ES cell proliferation. (A) qRT-PCR confirmation of LGR5
knockdown in ES cell lines transduced with LGR5 -targeted shRNAs
(shNS=non-silencing control). (B) Confirmation of LGR5 over-expression in
A673 cells transduced with LGR5 over-expression construct (Empty, empty
vector control). (C) ES cell expansion was measured by MTS assay and was
not affected by LGR5 knockdown. (D) LGR5 over-expression did affect cell
growth in A673 cells. (E) Parental cell growth was not affected by the addition
of WNT3A and/or RSPO2 to standard culture conditions. All data shown is
from two independent experiments and error bars are SEM.
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demonstrated heterogeneity of LGR5 expression and shown that
high LGR5 levels are associated with worse outcomes (Becker et al.,
2010; Simon et al., 2012; Wu et al., 2012; Nakata et al., 2013). Like-
wise, several studies have found a connection between high LGR5
expression and chemoresistance (Bauer et al., 2012) and metastasis
(Uchida et al.,2010; Takahashi et al., 2011;Valladares-Ayerbes et al.,
2012; Wu et al., 2012) in gastrointestinal malignancies. Interest-
ingly, recent studies in mouse models of neuroblastoma (Balamuth
et al., 2010) and medulloblastoma (Kawauchi et al., 2012) also
discovered increased expression of Lgr5 in the most aggressive
tumors. Thus, there is now substantial evidence in tumors of both
epithelial and neural origin to implicate LGR5 as a marker of an
aggressive cellular phenotype. Data to support a potential role for
LGR5 in tumors of mesenchymal origin is also now beginning to
emerge. A recent report by Rot et al. (2011) described a novel splice
variant of LGR5 in the context of soft tissue sarcoma and reported
that low level expression of this variant transcript (which lacks
exon 5) was associated with worse overall and event free survival.
In addition, the LGR5 locus was recently identified to be among
the most frequently amplified loci in a genome-wide study of soft
tissue sarcomas (copy number in top 1% of nearly 19,000 genes)
suggesting that up-regulation of LGR5 may contribute to sarcoma
pathogenesis (Barretina et al., 2010). Our current study adds ES
to the list of tumors where LGR5 may serve as a marker of aggres-
sive disease. We are now actively pursuing this hypothesis in large
cohorts of primary tumor samples as well as model systems.
Although LGR5 was identified some years ago as a Wnt-
responsive gene, its role as a potentiating receptor upstream of
Wnt signaling was only recently discovered (Carmon et al., 2011;
de Lau et al., 2011; Glinka et al., 2011; Gong et al., 2012). LGR5
and its related receptor family members LGR4 and LGR6 have now
all been established as a receptors for the RSPO-family of ligands,
which act to potentiate Wnt/β-catenin signaling by complexing
with Frizzled/LRP receptors (Carmon et al., 2011; de Lau et al.,
2011; Glinka et al., 2011; Gong et al., 2012). There is now substan-
tial evidence that hijacking of Wnt signaling may be important for
the initiation and maintenance of ES, although the precise con-
tribution of β-catenin-dependent and – independent pathways
remains to be elucidated (Uren et al., 2004; Miyagawa et al., 2009;
Navarro et al., 2010; Vijayakumar et al., 2011; Hauer et al., 2013).
Significantly, Uren et al. (2004) measured expression of the canon-
ical Wnt ligands WNT1, WNT2, and WNT3 and found them to
be undetectable in ES. In addition, only low levels of β-catenin
nuclear localization were detected in cell lines and tumor sam-
ples. Likewise, Navarro et al. (2010) reported low levels of basal
TCF transcriptional activity in ES cell lines. Studies of DKK1 and
DKK2, known modulators of Wnt signaling, have demonstrated
that while the former is repressed in ES (Navarro et al., 2010)
the latter is induced by EWS-FLI1 and promotes cellular inva-
sion and metastasis (Miyagawa et al., 2009; Hauer et al., 2013).
In addition, a recent report showed that the non-canonical Wnt,
WNT5A, induces ES cell migration and that the Wnt inhibitor
SFRP5 is silenced in ES cells by DNA promoter methylation (Jin
et al., 2012). Thus, although there is still much to be understood
about the role of Wnt signaling in ES pathogenesis, the data thus
far support a more dominant role for Wnt deregulation in alter-
ing cell morphology, motility, and invasion rather than classical
β-catenin-mediated cellular proliferation. Consistent with these
prior reports we found that, in standard culture conditions, basal
levels of Wnt/β-catenin signaling are low. In addition, despite
the fact that Wnt3a and RSPO2 were able to robustly activate
and potentiate canonical Wnt signaling, respectively, we did not
observe changes in cellular proliferation. Even the addition of
RSPO2 to the culture media of LGR5-high CHLA25 cells had
no impact on cell proliferation. Likewise, LGR5 knockdown had
no discernible impact on the expression of Wnt/β-catenin target
gene expression nor TCF reporter activity under basal conditions.
However, when growth medium was supplemented with Wnt3a,
β-catenin nuclear localization, and TCF transcriptional activity
were robustly activated. In ES cells that express LGR5 this signal-
ing was further potentiated by the addition of RSPO2 confirming
a functional role for this receptor in cells that are exposed to LGR5
ligand. Thus, our results together demonstrate that, in the presence
of appropriate ligands, Wnt/β-catenin signaling can be stimulated
in ES cells and this stimulation is maximal in cells that express
high levels of LGR5. The phenotypic effects of this increased Wnt
activity remain unclear but our studies thus far suggest that pro-
liferation is unaffected and that both cell autonomous as well
microenvironmental factors combine to determine the functional
consequences of enhanced Wnt signaling and nuclear β-catenin
localization in LGR5+ ES cells.
Emerging evidence from other model systems supports the pos-
sibility that LGR5 function might be highly contextually depen-
dent. Mouse studies have shown that Lgr5 is widely expressed
during embryogenesis but only becomes limited to discrete stem
cell populations post-natally, in particular stem cells of hair folli-
cles and the gastrointestinal tract (Barker et al., 2007; Barker and
Clevers, 2010). In normal stem cells secretion of RSPO from neigh-
boring cells supports Lgr5-dependent self-renewal and prolifera-
tion by activating canonical Wnt signaling (Barker and Clevers,
2010). Likewise, the initiation and proliferation of intestinal ade-
nomas and carcinomas is driven by Lgr5+ stem cells (Barker et al.,
2009; Schepers et al., 2012). However, data from both colorectal
carcinoma cell lines as well as other tumor types complicate the
scenario. Consistent with our own data, Walker et al. (2011) found
that LGR5 did not affect proliferation of colorectal cancer cell lines
but instead negatively regulated Wnt signaling, colony formation,
and migration. Thus, in this cellular context LGR5 functioned
more as a tumor suppressor than tumor promoter. In addition,
promoter hypermethylation and loss of function mutations in
LGR5 and LGR6 have been discovered in some colorectal tumor
samples, again suggesting that these genes could act as tumor sup-
pressors in some contexts (Sjoblom et al., 2006; Chan et al., 2008;
de Sousa et al., 2011). These conflicting reports demonstrate that
LGR5 has differing roles during development and in different cel-
lular contexts. Thus, its contribution to cancer maintenance and
progression is likely to be determined by both the genetic and
epigenetic state of the affected cell as well as the surrounding
microenvironment.
The mechanism of transcriptional up-regulation of LGR5 in
ES cell populations is unknown. Importantly, however, LGR5 is
not induced by EWS-FLI1 and unpublished data from our own
lab as well a previously published report (see Navarro et al., 2010
supplementary data) suggest that LGR5 is, in fact, repressed by
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EWS-FLI1. Thus, we reasoned that expression of LGR5 in ES cells
may instead be a reflection of their putative stem cell origins.
Interestingly, among different neuro-mesenchymal stem cell pop-
ulations we discovered that undifferentiated NCSC expressed the
highest levels of LGR5. Expression was still detectable, albeit at
lower levels, in NCSC that had undergone epithelial-mesenchymal
transition to an MSC-state (von Levetzow et al., 2011). In con-
trast, bone marrow-derived MSC did not express detectable levels
of LGR5. Intriguingly, it is now established that rare MSC in the
bone marrow are derived from the neural crest (Takashima et al.,
2007; Nagoshi et al., 2008) and gene expression profiling data from
mouse MSC (GEO accession GSE30419) showed increased expres-
sion of Lgr5 in neural crest-compared to mesoderm-derived MSC
populations (Wislet-Gendebien et al., 2012). Based on these stud-
ies we now speculate that at least some ES might arise from neural
crest-derived LGR5+ stem cells in the bone marrow. Further, we
speculate that the RSPO-rich microenvironment of developing
bone may contribute to malignant transformation of these LGR5+
cells in the event that they acquire an EWS-ETS fusion. Ongo-
ing studies in our laboratory are now specifically addressing these
intriguing hypotheses.
In summary, we have shown that LGR5 is expressed by ES, in
particular by putative cancer stem cells and, in the context of a Wnt
and RSPO-rich microenvironment, LGR5 functions to potentiate
canonical Wnt/β-catenin signaling. In addition, we have discov-
ered that LGR5 is expressed by neural crest-derived stem cells,
putative cells of ES origin, demonstrating that LGR5 may also
be a marker of some non-epithelial stem cells. Given the pro-
found complexity of Wnt signaling and its dependence on both cell
autonomous as well as microenvironmental cues it is now essen-
tial that functional studies of LGR5 and the Wnt/β-catenin axis in
ES be performed in model systems that faithfully recapitulate the
in vivo tumor microenvironment.
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